This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Dr. Peter Sullivan discussing financial toxicity in testicular cancer ...

SUVmax cut point of 9 is associated with a: 33-fold higher risk of high risk pathology in radical prostatectomy specimens with a PPV of 81% 24-fold higher risk of high risk disease features in radical ...

Patients were further queried to identify those who received adequate BCG induction (defined as ≥ 5 weekly instillations). They then summarized the distribution of this group and the treatments ...

Additionally, it is the only nephron sparing approach that offers relative oncologic certainty by yielding complete pathological information about the excised tumor. Indeed, we know that partial ...

(UroToday.com) The 2024 South Central AUA annual meeting included a session on prostate cancer, featuring a presentation by Dr. Gal Saffati discussing a systematic review regarding whether veterans ...

(UroToday.com) The 2024 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation by Dr. Chad LaGrange discussing the case for radical cystectomy as treatment for ...

The 2024 South Central AUA annual meeting included the Sushil Lacy manuscript competition, featuring a presentation by Dr. Amanda Myers discussing the elucidation of response rates to additional BCG ...

Statement 25: Clinicians should consider thermal ablation as an alternate approach for the management of cT1a solid renal masses <3 cm in size. For patients who elect thermal ablation, a percutaneous ...

The 2024 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation by Dr. Tyler Robin discussing indications and outcomes for radiation therapy in renal masses. Dr ...

Challenges in Transitioning Men from Active Surveillance to Watchful Waiting - Lisa Lowenstein ...

Nivolumab and ipilimumab (NIVO+IPI) is standard therapy for patients with intermediate and poor risk advanced renal cell carcinoma (RCC). However, the efficacy and safety of NIVO+IPI in elderly ...